- $46.84m
- $32.72m
- $3.40m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.54 | ||
| Price to Tang. Book | 7.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 13.77 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -163% | ||
| Return on Equity | -150.02% | ||
| Operating Margin | -1244.64% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 1.49 | 2.97 | 3.4 | 3.58 | 15.97 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Directors
- Last Annual
- June 30th, 2023
- Last Interim
- June 30th, 2023
- Incorporated
- March 15th, 2018
- Public Since
- November 6th, 2018
- No. of Employees
- 80
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 126,219,016
- Address
- Finsgate, 5-7 Cranwood Street, LONDON, EC1V 9EE
- Web
- https://renalytix.com/
- Phone
- +44 2920710570
- Auditors
- PKF Littlejohn LLP
Similar to RNLX
908 Devices.
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Brainsway
NASDAQ Global Market
Castle Biosciences
NASDAQ Global Market
FAQ
As of Today at 19:18 UTC, shares in Renalytix are trading at $0.80. This share price information is delayed by 15 minutes.
Shares in Renalytix last closed at $0.80 and the price had moved by -66.3% over the past 365 days. In terms of relative price strength the Renalytix share price has underperformed the S&P500 Index by -71.96% over the past year.
The overall consensus recommendation for Renalytix is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Renalytix does not currently pay a dividend.
Renalytix does not currently pay a dividend.
Renalytix does not currently pay a dividend.
To buy shares in Renalytix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.80, shares in Renalytix had a market capitalisation of $46.84m.
Here are the trading details for Renalytix:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: RNLX
Based on an overall assessment of its quality, value and momentum Renalytix is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Renalytix is $3.98. That is 396.2% above the last closing price of $0.80.
Analysts covering Renalytix currently have a consensus Earnings Per Share (EPS) forecast of -$0.34 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Renalytix. Over the past six months, its share price has underperformed the S&P500 Index by -43.73%.
As of the last closing price of $0.80, shares in Renalytix were trading -41.13% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Renalytix PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Renalytix's directors